{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:05:15Z","timestamp":1794024315051,"version":"4.8.0"},"reference-count":26,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Agents, such as \u03b2-lapachone, that target the redox enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1), to induce programmed necrosis in solid tumors have shown great promise, but more potent tumor-selective compounds are needed. Here, we report that deoxynyboquinone kills a wide spectrum of cancer cells in an NQO1-dependent manner with greater potency than \u03b2-lapachone. Deoxynyboquinone lethality relies on NQO1-dependent futile redox cycling that consumes oxygen and generates extensive reactive oxygen species (ROS). Elevated ROS levels cause extensive DNA lesions, PARP1 hyperactivation, and severe NAD+\/ATP depletion that stimulate Ca2+\u2013dependent programmed necrosis, unique to this new class of NQO1 \u201cbioactivated\u201d drugs. Short-term exposure of NQO1+ cells to deoxynyboquinone was sufficient to trigger cell death, although genetically matched NQO1\u2212 cells were unaffected. Moreover, siRNA-mediated NQO1 or PARP1 knockdown spared NQO1+ cells from short-term lethality. Pretreatment of cells with BAPTA-AM (a cytosolic Ca2+ chelator) or catalase (enzymatic H2O2 scavenger) was sufficient to rescue deoxynyboquinone-induced lethality, as noted with \u03b2-lapachone. Investigations in vivo showed equivalent antitumor efficacy of deoxynyboquinone to \u03b2-lapachone, but at a 6-fold greater potency. PARP1 hyperactivation and dramatic ATP loss were noted in the tumor, but not in the associated normal lung tissue. Our findings offer preclinical proof-of-concept for deoxynyboquinone as a potent chemotherapeutic agent for treatment of a wide spectrum of therapeutically challenging solid tumors, such as pancreatic and lung cancers. Cancer Res; 72(12); 3038\u201347. \u00a92012 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-11-3135","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T23:43:12Z","timestamp":1335310992000},"page":"3038-3047","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis"],"prefix":"10.1158","volume":"72","author":[{"given":"Xiumei","family":"Huang","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"},{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Dong","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"},{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A.","family":"Bey","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"},{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Kilgore","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Bair","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Shan","family":"Li","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"},{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malina","family":"Patel","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"},{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth I.","family":"Parkinson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiguang","family":"Wang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle S.","family":"Williams","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Gao","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Hergenrother","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Boothman","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"},{"name":"Authors' Affiliations: Departments of 1Pharmacology, 2Radiation Oncology, and 3Biochemistry, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, Texas; and 4Department of Chemistry, Roger Adams Laboratory, University of Illinois at Urbana-Champaign, Urbana, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2012,6,14]]},"reference":[{"key":"2022061703534233900_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/onc.2010.460","article-title":"Towards novel paradigms for cancer therapy","volume":"30","author":"Pavet","year":"2011","journal-title":"Oncogene"},{"key":"2022061703534233900_bib2","doi-asserted-by":"crossref","first-page":"33684","DOI":"10.1074\/jbc.M603678200","article-title":"Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair","volume":"281","author":"Bentle","year":"2006","journal-title":"J Biol Chem"},{"key":"2022061703534233900_bib3","doi-asserted-by":"crossref","first-page":"8088","DOI":"10.1158\/0008-5472.CAN-10-1418","article-title":"Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation","volume":"70","author":"Dong","year":"2010","journal-title":"Cancer Res"},{"key":"2022061703534233900_bib4","doi-asserted-by":"crossref","first-page":"11832","DOI":"10.1073\/pnas.0702176104","article-title":"An NQO1- and PARP1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone","volume":"104","author":"Bey","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703534233900_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0076-6879(04)82008-1","article-title":"NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics","volume":"382","author":"Ross","year":"2004","journal-title":"Methods Enzymol"},{"key":"2022061703534233900_bib6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ctrv.2004.01.002","article-title":"DT-diaphorase: a target for new anticancer drugs","volume":"30","author":"Danson","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"2022061703534233900_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clon.2007.03.006","article-title":"Bioreductive drugs: from concept to clinic","volume":"19","author":"McKeown","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2022061703534233900_bib8","first-page":"3083","article-title":"A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent","volume":"4","author":"Winski","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2022061703534233900_bib9","first-page":"6102","article-title":"Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas","volume":"43","author":"Curt","year":"1983","journal-title":"Cancer Res"},{"key":"2022061703534233900_bib10","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1074\/jbc.275.8.5416","article-title":"NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity","volume":"275","author":"Pink","year":"2000","journal-title":"J Biol Chem"},{"key":"2022061703534233900_bib11","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1158\/1078-0432.CCR-04-2185","article-title":"Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels","volume":"11","author":"Reinicke","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2022061703534233900_bib12","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1158\/0008-5472.CAN-09-3995","article-title":"Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy","volume":"70","author":"Blanco","year":"2010","journal-title":"Cancer Res"},{"key":"2022061703534233900_bib13","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1021\/ja100610m","article-title":"Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death","volume":"132","author":"Bair","year":"2010","journal-title":"J Am Chem Soc"},{"key":"2022061703534233900_bib14","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0006-2952(03)00013-3","article-title":"Cytotoxicity and apoptosis of benzoquinones: redox cycling, cytochrome c release, and BAD protein expression","volume":"65","author":"Tudor","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"2022061703534233900_bib15","first-page":"1876","article-title":"Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone","volume":"58","author":"Wuerzberger","year":"1998","journal-title":"Cancer Res"},{"key":"2022061703534233900_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/1078-0432.CCR-10-1983","article-title":"Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy","volume":"17","author":"Li","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2022061703534233900_bib17","doi-asserted-by":"crossref","first-page":"40485","DOI":"10.1074\/jbc.M607704200","article-title":"Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells","volume":"281","author":"Criddle","year":"2006","journal-title":"J Biol Chem"},{"key":"2022061703534233900_bib18","first-page":"2065","article-title":"Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors","volume":"4","author":"Siegel","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2022061703534233900_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0378-4274(01)00426-X","article-title":"NAD(P)H: quinone oxidoreductase 1 expression in human bone marrow endothelial cells","volume":"125","author":"Siegel","year":"2001","journal-title":"Toxicol Lett"},{"key":"2022061703534233900_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0076-6879(04)82018-4","article-title":"Induction of NQO1 in cancer cells","volume":"382","author":"Begleiter","year":"2004","journal-title":"Methods Enzymol"},{"key":"2022061703534233900_bib21","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1073\/pnas.90.15.7200","article-title":"Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells","volume":"90","author":"Boothman","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703534233900_bib22","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1593\/neo.07397","article-title":"Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells","volume":"9","author":"Choi","year":"2007","journal-title":"Neoplasia"},{"key":"2022061703534233900_bib23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/bjc.1997.485","article-title":"DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours","volume":"76","author":"Marin","year":"1997","journal-title":"Br J Cancer"},{"key":"2022061703534233900_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/mc.20107","article-title":"Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer","volume":"43","author":"Lewis","year":"2005","journal-title":"Mol Carcinogenesis"},{"key":"2022061703534233900_bib25","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1349-7006.1998.tb00648.x","article-title":"Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase","volume":"89","author":"Mikami","year":"1998","journal-title":"Jpn J Cancer Res"},{"key":"2022061703534233900_bib26","doi-asserted-by":"crossref","first-page":"19150","DOI":"10.1074\/jbc.M100730200","article-title":"Calcium is a key signaling molecule in beta-lapachone-mediated cell death","volume":"276","author":"Tagliarino","year":"2001","journal-title":"J Biol Chem"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/72\/12\/3038\/2668757\/3038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/72\/12\/3038\/2668757\/3038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T09:35:06Z","timestamp":1655458506000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/72\/12\/3038\/575597\/An-NQO1-Substrate-with-Potent-Antitumor-Activity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,14]]},"references-count":26,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,6,14]]},"published-print":{"date-parts":[[2012,6,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-11-3135","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22391754","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391739.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391742","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391751","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391748.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391745.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391742.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391736.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391739","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391751.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391748","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391736","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391754.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22391745","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6503331.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6503331","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,14]]}}}